Molecular oncogene markers and their significance in cutaneous malignant melanoma

Annals of Surgical Oncology

Volumn 5, Issue 3, 1998, Pages 253-260

  Konstadoulakis, Manoussos M ^a   Vezeridis, Michael ^a   Hatziyianni, Emi ^b   Karakousis, Constantine P ^b   Cole, Bernard ^a   Bland, Kirby I ^a   Wanebo, Harold J ^a,c  

^a BROWN UNIVERSITY   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c ROGER WILLIAMS MEDICAL CENTER   (United States)

Author keywords

C myc oncogene; HLA DR antigen; HSP 70; Malignant melanoma; Node dissection; Prognostic factors

Indexed keywords

HEAT SHOCK PROTEIN 70; HLA DR ANTIGEN; MYC PROTEIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MELANOMA; ONCOGENE; PROGNOSIS;

ADULT; AGED; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HLA-DR ANTIGENS; HSP70 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MYC; REPRODUCIBILITY OF RESULTS; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT FAILURE; TUMOR MARKERS, BIOLOGICAL;

EID: 0031811736     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02303782     Document Type: Article

References (30)

1. Cajal SR, Suster S. Halaban R, et al. Induction of different morphologic features of malignant melanoma and pigmented lesions after transformation of murine melanocytes with bFGF-cDNA and H-ras. myc, neu and Ela oncogenes. Am J Path 1991;138:349-58.
2. Runger M, Klein CE, Becter JC, Brocker EB. The role of genetic instability, adhesion, cell motility and immune escape mechanisms in melanoma progression. Curr Opin Oncol 1994;6:188-96.
3. Lindquist S, Craig EA. The heat-shock proteins. Annu Rev Genet 1988;22:631-77.
4. Cole MD. The myc oncogene: its role in transformation and differentiation. Annu Rev Genet 1986;20:361-84.
5. Bennet SH, Futrel JW, Roth J, et al. Prognostic significance of histologic host response in cancer of the larynx or hypolarynx. Cancer 1971;28:1255-6.
6. Berg JW. Morphological evidence for immune response to breast cancer. A histologic review. Cancer 1971;28:1453-6.
7. Balch CM, Soong SJ et al. A comparison of prognostic factors and surgical results in 1,786 patients with localized (Stage I) melanoma treated in Alabama, USA and New South Wales, Australia. Ann Surg 1982;1196:677.
8. McCarthy WH, Shaw HM, Milton GW. Efficacy of elective lymph nodes of patients with pathological stage I malignant melanoma. Am J Surg Pathol 1988;12:612-18.
9. Veronesi U, Adamaus J, Bandiera DC, et al. Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities. Cancer 1982;49:2420-30.
10. Sim FH, Taylor WF, Pritchard DJ, Soule EH. Lymphadenectomy in the management of stage I malignant melanoma: A prospective randomized study. Mayo Clin Proc 1986;61:697-705.
11. Balch CM, Soong S-J, Bartolucci AA, et al. Efficacy of an elective regional lymph node dissection of 1- to 4-mm thick melanomas for patients 60 years of age and younger. Ann Surg 1996;224:255-66.
12. Cochran AJ, Wen D-R, Morton DL. Occult tumor cells in the lymph nodes of patients with pathological stage I malignant melanoma. Am J Surg Pathol 1988;12:612-18.
13. 12a. Morton DL, Wen DR, Wonj JH, et al. Technical details of intra-operative lymphatic mapping for early stage melanoma. Arch Surg 1992;127:392.
14. Mattei E, Damas D, Milco AM, Delpino A, Ferrini V. Stress response, survival and enhancement of heat sensitivity in a human melanoma cell line treated with L-Conavanine. Anticancer Res 1992;12:757-62.
15. Steels El., Watson K, Parsons PB. Relationship between thermo tolerance, oxidative stress responses and induction of stress proteins in human tumor cell lines. Biochem Pharma 1992;44:2123-9.
16. Delpino A, Sponsanti P, Mattei E, Milco AM, Vismara D. Ferrini U. Identification of a 66kD heat shock protein (HSP) Induced in M-14 human melanoma cells by severe hyperthermia treatment. Melanoma Res 1992;2:369-75.
17. Carper SW, Duffy JT, Gerner EW. Heat shock proteins in thermotolerance and other cellular processes. Cancer Res 1987;47: 5249-55.
18. Storm FK, Mahvi DM, Gilchrist KW. HSP-27 is not expressed and has no prognostic significance in rectal adenocarcinoma. Reg Cancer Treat 1993;3:146-8.
19. Storm FK, Gilchrist KW, Warner TF et al. Distribution of HSP-27 and her-2/neu in in-situ and invasive ductal breast carcinomas. Ann Surg Oncol 1985;2:43-8.
20. Symonds G, Klempmauer KH, Snyder M, Moscovici G. Moscovici C, Bishop JM. Coordinate registration of myelomonocytic pheno-type by v-myb and v-myc. Mol Cell Biol 1986;6:1796-1802.
21. Johnson JP, Lehman JM, Stade BG, et al. Functional aspects of three molecules associated with metastatic development in human malignant melanoma. Invasion Metastasis 1989;9:338-50.
22. Bauer J, Sokol L, Stribma J. et al. Amplification of N-myc oncogene in human melanoma cells. Neoplasma 1990;37:233-8.
23. Bhan AK, Desmarais CV. Immunohistologic characterization of major histocompatibility antigens and inflammatory cellular infiltrates in human breast cancer J Natl Cancer Inst 1983;71:507-13.
24. Shimokawara IM, Yamanaka N, et al. Identification of lymphocyte subpopulations in human breast cancer tissue and its significance. Cancer 1982;49:1456-64.
25. Ruiter DJ, Bran AK, Harist TJ, et al. Major histocompatibility antigens and mononuclear inflammatory infiltrates in benign nevomelanocytic proliferation and malignant melanoma. J Immunol 1982;129:2815.
26. Thorsby E, Bergholtz B, Berlest, et al. Involvement of HLA in T-cell immune responses. Transplant Proc 1981;13:903-8.
27. Balch CM. Immune responses to tumor antigens and their clinical applications. Surgery 1986;100:562-71.
28. Bhan AK, Perry LL, Cantor H, et al. The role of T cell sets in the rejection of methylcholanthrene induced sarcoma (S 1509a) in syngeneic mice. Am J Pathol 1981;102:20-7.
29. Colloby PS, West KP, Fletcher A. Is poor prognosis really related to HLA-Dr expression by malignant melanoma cells? Histopathology 1992;20:411-6.
30. Munzarova M, Zemanova D, Rejthar A, et al. HLA-DR antigen expression on melanoma metastases and the course of the disease. Cancer Immunol Immunother 1989;3:185-9.